Detail akcie Sight Sciences Rg online

Business Summary: Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Sight Sciences Inc revenues decreased 6% to $57M. Net loss decreased 14% to $34.3M. Revenues reflect Dry Eye segment decrease of 75% to $915K, Surgical Glaucoma segment decrease of 2% to $56.1M. Lower net loss reflects Selling, general, and administrative - B decrease of 6% to $61.5M (expense), Stock-based Compensation in SGA decrease of 22% to $8.6M (expense).